IVF vs MARA vs NTRA vs RIOT vs EXAS

For growth investors, INVO Fertility, Inc.

(IVF) is the stronger pick with 116. 3% revenue growth year-over-year, versus 17. 7% for Exact Sciences Corporation (EXAS). Analysts rate Marathon Digital Holdings, Inc. (MARA) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +114. 4%, compared to -100. 0% for INVO Fertility, Inc. (IVF). Over 10 years, the gap is even starker: NTRA returned +1835% versus IVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

05β versus Riot Platforms, Inc. 's 3. 92β — meaning RIOT is approximately 7358% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Riot Platforms, Inc. (RIOT) carries a lower debt/equity ratio of 10% versus 105% for Exact Sciences Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), INVO Fertility, Inc.

(IVF) is pulling ahead at 116. 3% versus 17. 7% for Exact Sciences Corporation (EXAS). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -673. 5% for Riot Platforms, Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exact Sciences Corporation (EXAS) is the more profitable company, earning -6.

4% net margin versus -144. 6% for Marathon Digital Holdings, Inc. — meaning it keeps -6. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXAS leads at -6. 4% versus -124. 4% for IVF. At the gross margin level — before operating expenses — EXAS leads at 69. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NTRA: 36.

8% to $265. 63.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), +1669% 10Y return). Marathon Digital Holdings, Inc. (MARA) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, MARA: -50. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IVF (Healthcare) and MARA (Financial Services) and NTRA (Healthcare) and RIOT (Financial Services) and EXAS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.